Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > BUSINESS
BUSINESS
- Astagraf XL, Tacrolimus Extended-Release Capsules, Approved in US: Astellas
July 24, 2013
- Kyowa Kirin Files Poteligeo for PTCL, CTCL in Japan
July 23, 2013
- Toho University Prof. Nakamura Says Prasugrel Promising in Preventing Platelet Clotting
July 22, 2013
- AD Treatment Lu AE58054 Improves Cognitive Performance in PII Study: Otsuka Pharmaceutical
July 22, 2013
- AD Biomarker TOMM40 Favorable in Detecting AD Risk: Takeda
July 19, 2013
- Xtandi Share May Increase as Second-Line Drug in US, Ranks Top as Third-Line Drug: Kantar Health
July 19, 2013
- Teribone’s Sales Growing Fast, Owing to High Demand of Drugs Promoting Bone Formation: Asahi Kasei Pharma President
July 19, 2013
- 60% Generic Share Target Is Highly Achievable: Daiichi Sankyo Espha President Yoshiwaka
July 19, 2013
- Novartis to Share Ex-Employee Hearing Info, Says “Gravely Concerned” about Media Reports
July 18, 2013
- Pfizer Paid 23.9 Billion Yen to Physicians, Medical Institutions in FY2012; 1st Disclosure under JPMA Guidelines
July 18, 2013
- BIKEN, JPRI to Merge in April
July 18, 2013
- MTPC to Strengthen Vaccine Development through Merger with Canadian Biotech Company Medicago
July 18, 2013
- Mylan Generics Will Be Distributed under Pfizer Brand Next Year: Pfizer’s Matsumori
July 17, 2013
- GSK Withdraws COPD Indication from NDA for ICS/LABA Combination Drug in Japan
July 17, 2013
- Astellas Launches Anticancer Agent Xtandi in UK
July 16, 2013
- Hisamitsu Initiates Domestic PII Study of Long-Acting Transdermal Allergic Rhinitis Treatment
July 16, 2013
- Manipulation of Data Cannot Be Confirmed Based on Results of University’s Investigation: Novartis Pharma
July 16, 2013
- Nippon Chemiphar Considers Establishing Manufacturing Base in Vietnam
July 16, 2013
- Otsuka Forms Clinical Research Firm in UK as Europe’s R&D Hub
July 12, 2013
- Cancer, CNS Diseases to Be Important Fields for MSD Over Next 10 Years: Pres. Alvarez
July 12, 2013
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…